Concepedia

Sandra W. Cowan‐Jacob

SW

Statistics

Publications

37

Citations

7K

H-Index

30

Active since

1996

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

University of Basel

Dana-Farber Cancer Institute

Novartis (United States)

Sandra W. Cowan‐Jacob is an author at Novartis (Switzerland) specializing in medicinal chemistry, drug discovery, and pharmacology.

ORCID

Publications per year

1996–2020

37

Publications

37

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

, , +6

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

Thomas O’Hare, Denise K. Walters, Eric P. Stoffregen et al. · Cancer Research · 2005 · 1K citations · Full text

, , +10

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke et al. · Nature · 2010 · 599 citations

, , +14

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 596 citations

, , +15

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 447 citations · Full text

, , +14

1–5 of 37